The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Cancer has been one of the leading diseases responsible for the deaths of millions across the world every year. Cancer damages the immune system, as cancer cells produce self-antigen. The cancer vaccines play a vital role in the maintenance of the immune system, as they are considered to be biological response modifiers. According to the report, the global cancer vaccines market is anticipated to grow at a ~16.0% CAGR from 2019 to 2030.
Top Major Players of Cancer Vaccines Market
The prominent players operating in the global cancer vaccines market are AstraZeneca, Bavarian Nordics, GlaxoSmithKline, Pfizer Inc., CSL Limited, Sanofi Pasteur, Merck & Co., Inc., Bristol-Myers Squibb, Astellas Pharma Inc., Aduro BioTech, Inc., and Dendreon among others
Pharmaceutical companies have a considerable number of products under clinical trials and strong product pipeline for cancer vaccines is a major factor contributing to the extensive growth of the market. For instance, Bavarian Nordic’s CV301 + nivolumab (Colorectal cancer) and CV301 + atezolizumab (Bladder cancer) are currently under Phase II clinical trials. Similarly, AlphaVax’s, PSMA (prostate cancer) and TRP2 (melanoma) are under phase I/II and pre-clinical respectively.
No comments:
Post a Comment